论文部分内容阅读
目的:探讨基质金属蛋白酶-9(MMP-9)与2型糖尿病(2DM)发生早期大血管病变的关系。方法:170例2DM患者接受降糖、降压、降脂等综合性治疗,1年后有24例出现大血管病变,以此作为观察组;选择24例未发生大血管病变的患者作为对照组。比较2组MMP-9水平。结果:治疗1年后发生大血管病变的患者的MMP-9水平较对照组高[(167.2±112.0)μg/L∶(119.6±55.8)μg/L,P<0.05)]。结论:2DM患者早期大血管病变的发生与其血浆MMP-9浓度升高有关。
Objective: To investigate the relationship between matrix metalloproteinase-9 (MMP-9) and early-stage macrovascular disease in type 2 diabetes mellitus (2DM). Methods: One hundred and seventy patients with 2DM received comprehensive treatment of hypoglycemic, antihypertensive and lipid-lowering treatment. After one year, 24 patients had macrovascular disease, which was regarded as observation group. Twenty-four patients without macrovascular disease were selected as control group . The levels of MMP-9 in two groups were compared. Results: The levels of MMP-9 in patients with macroangiopathy after 1 year of treatment were significantly higher than those in the control group [(167.2 ± 112.0) μg / L: (119.6 ± 55.8) μg / L, P <0.05). Conclusion: The incidence of early macrovascular disease in 2DM patients is related to the increase of plasma MMP-9 concentration.